biote Corp. operates in medical practice-building business within the hormone optimization space.
Biote stock last closed at $5.40, up 2.47% from the previous day, and has decreased 40.13% in one year. It has underperformed other stocks in the Medical Care Facilities industry by 0.34 percentage points. Biote stock is currently +170% from its 52-week low of $2.00, and -25.52% from its 52-week high of $7.25.
As of May 26, 2023, there are 70.71M shares of BTMD outstanding. The market cap of BTMD is $381.86M. In the past 24 hours, 42,506 BTMD shares were traded.
You will need a brokerage account to access the NASDAQ market and buy BTMD stock.
Based on our experience, eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by creating an account with eToro now.
Open eToro AccountNow that you've chosen the best brokerage, the next step is to fill out some personal details so you are able to buy BTMD stock today.
Now that you've created your account on one of the most highly reviewed stock apps, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing funds into your investment account.
Once you have figured out the best place to buy Biote stock, it's critical to research their stock before you buy, so you actually comprehend the risk and opportunity.
WallStreetZen was built to help everyday investors do more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on BTMD's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge BTMD's intrinsic value.
You can do additional valuation analysis on BTMD's stock here.
Out of 1 Equities analysts who track BTMD, the consensus analyst rating on BTMD is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
George Kelly, a top 29% analyst from Roth MKM maintains BTMD with a strong buy rating and raises their BTMD price target from $10.00 to $11.00, on Mar 30, 2023.
Maintaining his Strong Buy rating, Kelly raised his price target on Biote Corp. by 10% following the release of the company's Q4 and FY 2022 earnings report on 2023/03/28.
The company's Q4 results and management's guidance were better than expected, the analyst summarized.
The stock remains inexpensive at just 6.3x the anticipated FY 2023 EBITDA, and management increased the size of the company's sales force by 50% in 2022, Kelly added.
Biote reported:
For Q4 2022:
For FY 2022:
For FY 2023, management guided:
CEO Terry Weber commented: “Our financial performance reflected successful execution of our growth strategy, as we further built our sales team and practitioner network in both existing and new geographic markets.
“In early January, we successfully completed a secondary offering of Biote Class A common stock, representing an important milestone in our journey as a public company. This transaction not only significantly increased the liquidity of our publicly traded shares, but also broadened institutional ownership of our shares. As a management team, we remain focused on building long-term shareholder value through profitable growth.
"In 2023 we anticipate continued growth in both revenue and adjusted EBITDA, as we further build our market presence and practitioner network. We are investing to strengthen our infrastructure and capabilities while continuing to expand our sales team.
"Our 2023 financial forecast assumes stronger revenue growth and adjusted EBITDA performance in the second half of the year as we begin to benefit from the contributions of sales personnel added at the end of last year."
You can dive deeper into what analysts are projecting on the Biote stock forecast page.
Last year, BTMD revenue was $172.66M. In the last one years, BTMD's revenue has gone up by 19.08% per year. This was faster than the Medical Care Facilities industry average of 9.35%.
Dig into BTMD's earnings and revenue performance here.
In the past 12 months, executives and large shareholders at BTMD have sold more shares than they have bought.
Mary Elizabeth Conlon, General Counsel of BTMD, was the latest BTMD insider to sell. They sold $64,386.98 worth of BTMD shares on Apr 4, 2023.
Get more info about who owns BTMD shares here.
No, Biote doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
There are two main types of orders:
Hit the Open button and eToro will place your order.
If you want more assistance investing in stocks on eToro, click the helpful video below:
Now that you own some BTMD shares, you'll want to stay up-to-date on your investment.
Put BTMD on a watchlist to get notified of the latest news about your BTMD stock.
To reiterate, here are the 6 steps for buying Biote stock:
If you require a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Biote, click below.